Therefore, CHK1 inhibitors can drive the activation of tumor immune responses and can also augment the activity of anti-PD-L1 therapy by upregulating intrinsic PD-L1 expression, which makes CHK1i combined with anti-PD-L1 reasonable for the treatment of endometrial cancer, but more research is required to explore this. This evidence concerns the gene CD274 and neoplasm.